ArticleBMC nephrology2025

Efficacy and safety of low- to medium-dose telitacicept in adults with high-risk progressive IgA nephropathy: a retrospective real-world study.

Juan Pei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.